Description
The project aims to characterize and evaluate the therapeutic efficacy of bispecific antibodies targeting checkpoint inhibitors of the LILRB family as monotherapy.
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02024-11-18$74,900
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2024-11-18(start date) | $74,900 | — | The project aims to characterize and evaluate the therapeutic efficacy of bispecific antibodies targeting chec… |
Related records · 11
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 805852886)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2025-2026-Q1-1029947 | National Research Council Canada | Conseil national de recherches Canada · CanExport SME | $13,000 | FY2026 |
| 172-2023-2024-Q3-1013458 | National Research Council Canada | Conseil national de recherches Canada · CanExport SME | $27,500 | FY2024 |
| 172-2022-2023-Q2-993841 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $490,750 | FY2023 |
| 172-2021-2022-Q4-984090 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $29,880 | FY2022 |
| 093-2021-2022-Q1-00129 | Canada Economic Development for Quebec Regions | Développement économique Canada pour les régions du Québec · Regional Relief and Recovery Fund (REGI-RRRF) | $372,000 | FY2022 |
| 033-2020-2021-Q4-513419 | Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada · SIF Stream 1- R&D | $13,442,000 | FY2021 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2024-2025-Q3-1024406 · retrieved 2026-11-15.